Cell Line-Specific Network Models of ER⁺ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Scientists used a network-based mathematical model to identify sensitivity regulators and drug combinations for the PI3Kα inhibitor alpelisib in ER+ PIK3CA mutant breast cancer. The combination of alpelisib and BH3 mimetics, e.g., MCL1 inhibitors, was experimentally validated in ER+ breast cancer cell lines.